Pancreatic Carcinoma Metastatic Clinical Trial
Official title:
A Phase II Study of Nab-paclitaxel and Gemcitabine, in Elderly Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Cancer incidence is increasing with age and the likelihood of elderly suffering from cancer
is 1:3. Although many clinical trials include elderly patients, no results for this subgroup
of patients are available. Since there is no specific recommendations for treatment of
elderly patients with pancreatic cancer, treatment with gemcitabine alone is the treatment of
choice for these patients.
Single-agent gemcitabine is the current standard of care, but the addition of cytotoxic and
targeted agents to gemcitabine has almost invariably provided no significant survival
improvement.
Results obtained recently in the MPACT phase III clinical trial in patients with pancreatic
cancer treated with nab-paclitaxel combined with gemcitabine have shown improvement in
overall survival, but due to in this clinical trial was included patients between 27 and 88
years, it is considered necessary to conduct a specific study for patients over 70 years.
The aim of this study is to investigate whether the clinical benefit of nab-paclitaxel
associated with gemcitabine can be extended to elderly patients with pancreatic cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01547260 -
Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04659603 -
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT03152487 -
Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis
|
N/A |